Pathogenesis of cancer involves a stepwise accumulation of genetic alterations that disrupt either the normal machinery of cell proliferation or its regulation by the activation of cellular oncogenes or inactivation of tumor suppressor genes. 1 Cellular proliferation is mediated by progression through the cell cycle, where two cell cycle checkpoints are located at G 1 S and G 2 M. Quiescent cells in G0 phase contain hypophosphorylated RB, which sequesters the transcription factor E2F. Upon activation by mitogens, upregulation of D-type cyclins results in activation of cyclin-dependent kinases (CDK), namely CDK4 and CDK6, resulting in phosphorylation of RB. Hyperphosphorylated RB results in release of E2F, which activates transcription of S1-specific genes, and irreversible commitment to cell cycle progression. Negative regulatory elements to the cell cycle progression include the INK4 (p15, p16, p18 and p19) and the CIP/KIP (p21 CIP , p27 KIP1 and p57 KIP2 ) families of proteins that give rise to cell cycle arrest.
1 P15, p16, p18 and p19 are coined INK4 family CDK inhibitors (CKI) as they share similar functional domains (ankyrin repeats for protein-protein interactions) that render them capable of competing with cyclin D for CDK4 and 6, and thus inhibition of CDKs 4 and 6.
Multiple myeloma (MM) is characterized by neoplastic proliferation of monoclonal plasma cells. These neoplastic plasma cells are believed to arise from a postgerminal center B cell, which migrates to the bone marrow, adheres to the marrow stroma, and triggers subsequent bone resorption and a paracrine cytokine loop. 2 The natural course of disease may progress through monoclonal gammopathy of undetermined significance (MGUS) to MM. MGUS is found in approximately 3% of persons older than 70 years and in 1% of those 50 years or older. During long-term follow-up, approximately one-fourth of patients develop MM, amyloidosis, macroglobulinemia, or other malignant lymphoproliferative disorders with a median interval of 10 years. 2 Aberrant gene promoter methylation is a mechanism whereby gene expression is abrogated. 3 It is therefore potentially involved in silencing of tumor suppressor genes during carcinogenesis. 3 We studied if disruption of the INK4/cyclin D-CDK/RB pathway is a common mechanism in the pathogenesis of MM and MGUS.
Diagnosis of MGUS is made in an asymptomatic patient with monoclonal gammopathy with a low level of M-component (IgG p3.5 g/dl, IgA p2 g/dl, and Bence Jones protein p1 g/ 24 h), less than 10% plasma cells in the bone marrow and absence of lytic bone lesions. High molecular weight genomic DNA was isolated by standard protocols from bone marrow aspirates of 34 patients with MM, six patients with MGUS and AF10 cell line (kindly provided by Professor Zelig Eshhar, Department of Immunology, Weizmann Institute of Science, Israel). The methylation-specific polymerase chain reaction (MSP) for gene promoter methylation was performed as described in detail previously. 3 Briefly, treatment of DNA with bisulfite for conversion of unmethylated, but not methylated, cytosine to uracil was performed with a commercially available kit (CpGenome DNA modification kit, Intergen, New York, USA) according to the manufacturer's instructions. The primers for the methylated (M-MSP) and unmethylated (U-MSP) gene promoter regions are shown in Table 1 . DNA from eight normal donors was used as negative control, while methylated control DNA (CpGenome Universal Methylated DNA, Intergen) was used as positive control in all the experiments. MSP was performed in a thermal cycler (9700, PE Biosystems, Foster City, CA, USA). The PCR mixture contained 50 ng of bisulfite-treated DNA, 0.2 mM dNTPs, 2 mM MgCl 2 , 10 pmol of each primer, 1 Â PCR Buffer II and 2.5 U AmpliTaq Gold (Perkin-Elmer Biosystems) in a final volume of 50 ml. The identity of the methylated and unmethylated sequences was confirmed by automated DNA sequencing. PCR products were gel purified, sequenced bidirectionally (ABI Prism dRhodamine Terminator Cycle Sequencing Kit, PE Biosystem), and analyzed on an automated DNA sequence analyser (377 ABI Prism, PE Biosystem).
None of the four genes tested were methylated in eight normal bone marrow samples. Normal marrow DNA showed unmethylated status by positive amplification in U-MSP but lack of amplification in M-MSP, and methylated positive control DNA showed complete methylation by positive amplification in M-MSP but not by U-MSP. The specificity of the MSP was verified by DNA sequencing of methylated positive control. DNA sequence of methylated control DNA is aligned and compared with germline sequence of the wild-type DNA (WT). Methylated cytosine residues in CpG dinucleotide remained as 'C', whereas unmethylated cytosine read as 'T' after bisulfite conversion.
At diagnosis, p16 hypermethylation occurred in 18 (52.9%) MM and none of the MGUS (P ¼ 0.02). Hypermethylation of p15 occurred in 12 (35.3%) MM patients and three (50%) MGUS patients (P ¼ 0.68). Concurrent p15 and p16 methylation occurred in six (17.6%) of patients with MM. None of the patients with MM and MGUS had methylation of p18 or RB. AF10 had completely unmethylated p15, p18 and RB but biallelic methylation of p16. In some patients with methylated DNA, the presence of amplification by U-MSP might be due to contamination by other cells in the marrow biopsy. However, hemizygous methylation cannot be excluded. Indeed, the absence of unmethylated band in the homogeneous cell line indicates biallelic methylation of p16 gene.
Ideally, MSP status of the neoplastic plasma cells will only be elucidated if marrow cells have been sorted for CD38-or CD138-positive cells. Here, MSP of the four genes has been first validated in eight normal control DNA by demonstration of the lack of methylation, and further verified by sequencing. Given that methylation detected by MSP is a positive signal with a high sensitivity (up to 1 Â 10 5 for p15 gene), 3 our results are still valid without sorting of the marrow for plasma cells.
Our study showed concurrent hypermethylation of p15 and p16 in a significant number of MM patients. This concurred with another study that reported frequent concurrent hypermethylation of both genes in myeloma patients. 4 This may imply that p15 and p16 methylation cooperated to disrupt the INK4/cyclin D1/RB cell cycle pathway. Indeed, one study in mantle cell lymphoma has shown disruption of this pathway either by concomitant hypermethylation of both p15 and p16, or concurrent p15 and p16 deletion. Similarly, another study showed frequent p16 hypermethylation together with either RB deletions or cyclin D1 overexpression in myeloma. Nonetheless, despite that both p15 and p16 inhibit cyclin-dependent kinases 4/6 by competing with cyclin D, previous studies suggest p15, but not p16, is upregulated in a TGFb-dependent manner. 4 Therefore, concurrent inactivation of p15 and p16 by hypermethylation, although members of the same cell cycle control circuitry, might represent inhibition of cell cycle pathway mediated by biologically distinct signals. Secondly, p15 gene is frequently codeleted in leukemic cells with p16 deletion because of their close proximity, as p15 and p16 are located within 20 kb of each other. 5 This might also account for the high frequency of concurrent methylation of both p15 and p16 in myeloma.
A similar frequency of p15 hypermethylation in both MGUS and MM suggested p15 methylation to be an early event. On the other hand, in contrast to the frequent methylation of p16 in MM, 4 there was absence of methylation of p16 in MGUS (P ¼ 0.02). Therefore, p16 methylation might be an event associated with progression to MM. Indeed, this notion was supported by a study of p16 methylation in a large cohort of patients with MGUS (N ¼ 40), MM (N ¼ 98) and plasma cell leukemia (N ¼ 5), 6 which showed frequent p16 methylation in 40% of MM and 80% of plasma cell leukemia, but not in any of the patients with MGUS. Furthermore, methylation studies in myeloma, acute leukemia and esophageal cancer also suggested p16 methylation to be associated with clonal evolution and disease progression. Therefore, the role of p16 methylation as a marker of progression to MM warrants further study. p18 is important in the terminal differentiation of B lymphocytes into plasma cell by the induction of cell cycle arrest. 7 Although frequent homozygous deletion (38%) of p18 genes has been reported in myeloma cell lines, deletion of the p18 has been identified in only 6% of patients with MM. 7 There is as yet no data on p18 gene methylation in MM, and our study showed absence of p18 hypermethylation in primary MM, MGUS and AF10 myeloma cell line.
RB, located in 13q14, has also been shown to be involved in an autocrine circuitry of IL-6-mediated myeloma cell growth. 8 Moreover, hemizygous RB deletion, due to 13q deletion, occurs frequently in MM. 8 However, in contrast to other studies that showed hypermethylation to cooperate with hemizygous gene deletion for biallelic inactivation of tumor suppressor genes, 8 our data did not show an important role of hypermethylation for complete suppression of RB.
In summary, both p15 and p16, but not p18 and RB, were frequently methylated. p15, but not p16, p18 and RB, was frequently methylated in MGUS. p16 hypermethylation might be a marker of progression to MM. GCG TTC GTA TTT TGC GGT T  CGT ACA ATA ACC GAA CGA CCG A  631C/35  148  9p21  U-MSP  TGT GAT GTG TTT GTA TTT TGT GGT T  CCA TAC AAT AAC CAA ACA ACC AA  154  p16  M-MSP  TTA TTA GAG GGT GGG GCG GAT CGC  GAC CCC GAA CCG CGA CCG TAA  651C/35  150  9p21  U-MSP  TTA TTA GAG GGT GGG GTG GAT TGT  CAA CCC CAA ACC ACA ACC ATA A  151  p18  M-MSP  TTATCGAATTGTTATTTTCGTTCG  CGTCTCGCCGAAAAAATAATC  641C/35  93  1p32  U-MSP  GGGTTATTGAATTGTTATTTTTGTTTG  CATCCATCTCACCAAAAAAATAATC  95  RB  M-MSP  GGGAGTTTCGCGGACGTGAC  ACGTCGAAACACGCCCCG  661C/35  152  13q14  U-MSP  GGGAGTTTTGTGGATGTGAT  ACATCAAAACACACCCCA  152 Tm: annealing temperature; M-MSP: methylation-specific polymerase chain reaction for the methylated allele; U-MSP: MSP for the unmethylated allele. Genomic abnormalities are emerging as crucial prognostic parameters in multiple myeloma (MM). Deletion of chromosome arm 13q (13qÀ) is present in 40-60% of tumors and has been recognized as an independent predictor of a dismal prognosis. Using chromosome banding analysis, only about a third of myelomas exhibit an abnormal karyotype. Moreover, evaluable metaphases are missing in up to one-fourth of cases, as shown in large cytogenetic studies. By molecular cytogenetic techniques, for example, comparative genomic hybridization (CGH) or fluorescence in situ hybridization (FISH), genomic changes can be identified in more than 90% of plasma cells primary tumors. While banding analyses fail to identify certain chromosomal aberrations, for example, small deletions or translocations with breakpoints located near the telomere, such abnormalities can be reliably detected by FISH. Therefore, FISH has become the most widely used tool for molecular diagnostics in MM today. Analogous to the acute and chronic leukemias, genomic aberrations most likely represent the biological basis of the clinical heterogeneity, that is also characteristic for MM. While our understanding of the implication of various translocations in MM has gradually increased, 1, 2 little is known about chromosomal imbalances in this disease. Even the exact incidence of most chromosomal gains and losses in MM are unknown to date. To address this issue, we developed a comprehensive, disease-specific DNA probe set for the evaluation of chromosomal imbalances in plasma cell malignancies and determined the incidence of genomic gains and losses in a large prospective series of myelomas.
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From August 1998 to November 2002, bone marrow aspirates from 357 consecutive patients diagnosed with MM were obtained for molecular cytogenetic analysis during routine diagnostic procedures. Of the 357 patients, 290 (81%) were entered on two national treatment trials and were newly diagnosed. The remaining patients had previous therapy. Informed consent was obtained from all patients. There were 141 female (39.5%) and 216 male patients (60.5%). Almost all patients had advanced stage myeloma (Salmon-Durie stage: II -21%, III -76%; others: 3%). At the time of specimen collection, the ages of the patients ranged from 28 to 76 years (median, 56 years). Mononuclear cells were separated by density-gradient centrifugation and cytospin preparations were performed. The quality of the cells and the proportion of tumor cells in the bone marrow samples were assessed by morphology on a MayGrü nwaldFGiemsa-stained cytospin preparation. Plasma cell enrichment using immunomagnetic beads directed against the CD138 antigen was performed in 29 specimens with a low tumor cell fraction. Tumor samples of insufficient cell quality (eg due to prolonged shipment to our central reference laboratory) or with o1% tumor cells after positive selection of plasma cells were not analyzed. Depending on the tumor cell light chain type, overnight incubation with the respective AMCA-labeled light chain antibody was used for the detection of myeloma cells during fluorescence microscopy. At least 100 AMCA-positive plasma cells were evaluated.
Based on our CGH study that resulted in the identification of genomic regions commonly gained or deleted in MM, 3 a comprehensive set of DNA clones for the detection of the most frequent chromosomal imbalances was assorted. To achieve high accuracy in diagnosis, probes were selected from the critical regions of these imbalances as delineated by CGH. This probe panel comprised probes mapping to chromosome bands 1p22, 1q21, 6q21, 8p11, 9q34, and 11q25. DNA clones from chromosome bands 13q14 (locus D13S272), 17p13 (p53), and 22q11 were added to this panel, as deletions involving these genomic loci have been previously reported to provide prognostic information in MM.
The following DNA clones were used: RPCI-11 71-L-20 (1q21.2), RPCI-11 210-F-08 (1q43), RPCI-11 284-J-03 (8p11.3),
